Jacobio Pharmaceuticals Group Co (HKSE:01167) EBIT : HK$-158.7 Mil (TTM As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Jacobio Pharmaceuticals Group Co EBIT?

Jacobio Pharmaceuticals Group Co's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2024 was HK$-176.4 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-158.7 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Jacobio Pharmaceuticals Group Co's annualized ROC % for the quarter that ended in Jun. 2024 was -108.87%. Jacobio Pharmaceuticals Group Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -150.80%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Jacobio Pharmaceuticals Group Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -8.41%.

Jacobio Pharmaceuticals Group Co EBIT Historical Data

The historical data trend for Jacobio Pharmaceuticals Group Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jacobio Pharmaceuticals Group Co EBIT Chart

Jacobio Pharmaceuticals Group Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EBIT

Get a 7-Day Free Trial

-1,793.20

-368.10

-412.73

-383.71

-157.28

Jacobio Pharmaceuticals Group Co Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
EBIT	Get a 7-Day Free Trial								-270.12	-177.75	-205.96	-176.36	17.63

Competitive Comparison of Jacobio Pharmaceuticals Group Co's EBIT

For the Biotechnology subindustry, Jacobio Pharmaceuticals Group Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Jacobio Pharmaceuticals Group Co's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jacobio Pharmaceuticals Group Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Jacobio Pharmaceuticals Group Co's EV-to-EBIT falls into.

Save Embed

;

Save Embed

;

Jacobio Pharmaceuticals Group Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-158.7 Mil.

Jacobio Pharmaceuticals Group Co (HKSE:01167) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Jacobio Pharmaceuticals Group Co's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

	ROC % (Q: Jun. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Jun. 2024 ))	/ count )
=	-410.276 * ( 1 - 0% )	/	( (417.797	+	335.885)	/ 2 )
=	-410.276	/	376.841
=	-108.87 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1597.443	-	126.031	-	( 1250.327	-	max(0, 224.367	-	1277.982	+	1250.327	))
=	417.797

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1413.245	-	108.984	-	( 1136.27	-	max(0, 193.501	-	1161.877	+	1136.27	))
=	335.885

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Jacobio Pharmaceuticals Group Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Jun. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-352.716	/	( ( (240.197 + max(-123.011, 0))	+	(227.597 + max(-103.901, 0)) )	/	2 )
=	-352.716	/	( ( 240.197	+	227.597 )	/	2 )
=	-352.716	/	233.897
=	-150.80 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	5.164)	-	(126.031	+	0	+	2.144)
=	-123.011

	Working Capital		(Q: Jun. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	5.0830000000001)	-	(108.984	+	0	+	2.8421709430404E-14)
=	-103.901

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Jacobio Pharmaceuticals Group Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jun. 2024 )
	=	-158.732	/	1886.311
	=	-8.41 %

Jacobio Pharmaceuticals Group Co EBIT Related Terms

Thank you for viewing the detailed overview of Jacobio Pharmaceuticals Group Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Jacobio Pharmaceuticals Group Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jacobio Pharmaceuticals Group Co Ltd (HKSE:01167) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

77V:Germany

Address

No. 88, Kechuang 6th Street, Building F2, Beijing Economic-Technological Development Area, Beijing, CHN

Website

https://www.jacobiopharma.com

Jacobio Pharmaceuticals Group Co Ltd is a clinical-stage pharmaceutical company focusing on the in-house discovery and development of innovative oncology therapies.

Executives

Qiming Corporate Gp Vi, Ltd.	2201 Interest of corporation controlled by you
Qiming Venture Partners Vi, L.p.	2101 Beneficial owner
Qiming Gp Vi, L.p.	2201 Interest of corporation controlled by you
Wang Yinxiang	2501 Other
Wang Xiaojie	2307 Founder of a discretionary trust who can infl
Hu Yunyan	2501 Other
Hillhouse Investment Management, Ltd.	2102 Investment manager
Hillhouse Fund Iv, L.p.	2201 Interest of corporation controlled by you
Hh Spr-iii Holdings Limited	2101 Beneficial owner
Shen Zhu	2501 Other
Ultimate Estate Limited	2201 Interest of corporation controlled by you
Treasure Partner International Limited	2501 Other
Gloryviewpharma Ltd	2501 Other
Honourpharma Ltd	2501 Other
Blesspharma Ltd	2501 Other

Jacobio Pharmaceuticals Group Co Headlines

No Headlines